Jennifer L. Good - Feb 14, 2022 Form 4/A - Amendment Insider Report for Trevi Therapeutics, Inc. (TRVI)

Role
President & CEO, Director
Signature
/s/ Christopher Galletta, attorney-in-fact
Stock symbol
TRVI
Transactions as of
Feb 14, 2022
Transactions value $
$0
Form type
4/A - Amendment
Date filed
7/1/2022, 04:41 PM
Date Of Original Report
Feb 15, 2022
Previous filing
Jun 11, 2021
Next filing
Jun 10, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TRVI Stock Option (right to buy) Award $0 +275K $0.00 275K Feb 14, 2022 Common Stock 275K $0.51 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This option was granted on February 14, 2022. The 275,000 shares of common stock underlying the option are scheduled to vest as to 25% of the shares on February 14, 2023 and as to the remaining 75% of the shares in equal monthly installments thereafter through February 14, 2026.
F2 This amendment to the Form 4 originally filed for the reporting person on February 15, 2022 is being filed solely to attach the power of attorney exhibit that was inadvertently excluded from the original filing.

Remarks:

Exhibit Index: 24 Power of Attorney